Deacylated lipopolysaccharide inhibits neutrophil adherence to endothelium induced by lipopolysaccharide in vitro by unknown
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A role for endothelial cells in the inflammatory response to Gram-negative
LPS issuggested by several linesofevidence: low doses ofLPS induce expression
of a cell surface factor(s) that increases the adherence of neutrophils to the
endothelial cell surface (1, 2), release of IL-1 (3, 4), release of an inhibitor of
tissue plasminogen activator (5, 6), and the expression of tissue factor (7). These
changes may contribute to the perivascular emigration of neutrophils and local
thrombosis that occur at sites ofGram-negative bacterial tissue invasion.
A standard experimental model for LPS tissue toxicity is the dermal Shwartz-
man reaction. Here an intradermal (preparative) injection of LPS provokes an
inflammatory reaction that is characterized by leukocyte adherence to endothe-
lium and then emigration of leukocytes from the vascular lumen into the
surrounding tissue space. When an intravenous injection of LPS is given 20-24
h later, hemorrhage and necrosis develop at the intradermal injection site (8).
The mechanism by which LPS initiates neutrophil adherence and migration in
this reaction is uncertain. Recent studies (9) have shown, however, that certain
structural requirements are necessary for lipid A, the toxic moiety of LPS, to
produce the dermal Shwartzman reaction: a glucosamine disaccharide, phos-
phates at positions 1 and 4, and at least one acyloxyacyl group. For example,
monophosphoryl lipid A, which lacks phosphate at carbon 1, does not prepare
the skin for the dermal Shwartzman reaction (9).
It was recently reported (10) that enzymatic removal ofthe nonhydroxylated
fatty acids that are attached by acyloxyacyl linkages to the ester- and amide-
linked long chain fatty acids ofthe lipid A region ofLPS reduces the activity of
LPS in the dermal Shwartzman reaction by a factor of 2:100. Since adherence
ofneutrophils to endothelium may contribute to the pathogenesis of the dermal
Shwartzman reaction, we studied the effects of LPS, enzymatically deacylated
LPS, lipid X (2,3-diacylglucosamine-I-phosphate [11], a nontoxic precursor of
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lipid A), and monophosphoryl lipid A on neutrophil adherence to cultured
human umbilical vein endothelium (HUVE).' We found that pretreatment of
HUVE with LPS markedly increased neutrophil adherence, whereas HUVE
pretreated with enzymatically deacylated LPS, lipid X, or monophosphoryl lipid
A failed to acquire adhesiveness for neutrophils. Of additional interest was our
finding that deacylated LPS, but not lipid X or monophosphoryl lipid A, inhibited
neutrophil adherence to HUVE induced by pretreatment of HUVE with LPS.
Materials and Methods
Reagents. Recombinant human tumor necrosis factor a (rhTNF-a) was a gift of
Genentech, Inc., South San Francisco, CA. The preparation, assayed (by the supplier) for
cytol~tic activity on actinomycin D-treated L929 mouse fibroblast cells, contained 5 .02
x 10 U/ml. Recombinant human IL-1 (rhIL-1) (109 U/ml) was purchased from Genzyme
(Boston, MA). The crystalline ditris salt of lipid X was provided by Dr. Ingolf Macher,
Sandoz Forschungsinstitut, Vienna, Austria (12). The crystalline material was dissolved in
chloroform/methanol 2:1 (vol/vol), aliquoted, dried under N2, and stored at -70°C.
Immediately before use, an aliquot of lipid X was dissolved in RPMI 1640 (M . A.
Bioproducts, Walkersville, MD) by waterbath sonication. Monophosphoryl lipid A from
Salmonella typhimurium was purchased from Ribi ImmunoChem Research, Inc. (Hamilton,
MT). It was suspended in PBS without Mg` or Ca"; (Grand Island Biological Co., Grand
Island, NY) and sonicated for 10-20 sec after warming to 65°C. Escherichia coli (055:135)
LPS, extracted by phenol-water (Westphal), was obtained from Sigma Chemical Co., St.
Louis, MO.
Preparation of Deacylated LPS.
￿
Biosynthetically radiolabeled Rc LPS were prepared
from S. typhimurium PRX20 as described (10, 13). The LPS contained 107,000 dpm of
'H-labeled fatty acid and 3,750 dpm of "C-labeledglucosamine per microgram. Enzymatic
deacylation was performed using acyloxyacyl hydrolase that was partially purified (-1,500-
fold enrichment in specific activity) from HL-60 cells. To produce maximal enzymatic
deacylation, LPS (20 jug) was incubated with enzyme for 72 h at 37°C in a reaction
mixture that contained BSA (1 mg/ml), 5 mM CaCl2, 0.5% (vol/vol) Triton X-100, and
20 mM Tris-citrate, pH 4.8. The reaction was stopped by precipitating the LPS and BSA
with three volumes of 95% ethanol. The precipitates were washed with 80% ethanol,
resuspended in pyrogen-free saline, and frozen in aliquots at -70'C. The percent
deacylation (percent loss of sH radioactivity from the LPS) was calculated by counting the
radioactivity in the precipitate and in the ethanol supernatant; analysis of the deacylated
LPS and the ethanol-soluble fatty acids by thin-layer chromatography indicated that the
maximally deacylated LPS (32% loss of sH radioactivity) retained ^-12% of the original
'H-nonhydroxylated fatty acids and >90% of the sH-3-hydroxytetradecanoate. Graded
deacylation was performed by incubatingconstant amounts ofenzyme and LPS for various
time intervals, as described (10). Control LPS, incubated in the reaction mixture without
enzyme, and the reaction mixture with enzyme, incubated without LPS, were precipitated
and stored as described for deacylated LPS.
Cell Culture. Endothelial cells were prepared by collagenase treatment of human
umbilical veins as previously described (14). Cultures were maintained in endotoxin-free
RPMI 1640 supplemented with 20% FCS (Hyclone, Sterile Systems, Logan, UT), heparin
(90 Fag/ml; Sigma Chemical Co.), and endothelial cell growth factor (150 tag/ml) as
described by Thornton et al. (15). Endothelial cell growth factor was prepared from
bovine hypothalamus according to the method of Maciag et al. (I6).
Neutrophil Isolation and Labeling.
￿
Peripheral blood was obtained by venipuncture from
healthy donors. The blood was collected in syringes containing heparin (10 U/ml), and
the neutrophils were isolated by Ficoll-Hypaque (Pharmacia Fine Chemicals, Piscataway,
'Abbreviations used in thispaper:
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NJ) gradient centrifugation, 3% dextran sedimentation, and hypotonic saline lysis (17).
This procedure resulted in a preparation >95% neutrophils, which exceeded 95% viability
of trypan blue dye exclusion. Isolated peripheral blood neutrophils were suspended in
PBS at 106 cells/ml and were labeled for 60 min at 37 °C with 1 PCi/Al
51 Cr as sodium
chromate, 1 mCi/ml, 200-500 Ci/g (New England Nuclear, Boston, MA) (18). After
labeling, the cells were washed three times with PBS and suspended ata final concentration
of 2 X 106 cells/ml in RPMI 1640 containing 1 % FCS and polymyxin B (10 wg/ml; Sigma
Chemical Co.).
Adherence Assay.
￿
5'Cr-labeled neutrophil adherence to HUVE was measured as previ-
ously described (1, 19). Primary cultures of HUVE were harvested with 0.05% trypsin
and 0.02% EDTA in HBSS (Gibco Laboratories, Grand Island, NY). The cells were then
plated in 11-mm diameter wells (Costar Cluster; Costar, Cambridge, MA) at 5 X 104
cells/well in RPMI 1640 supplemented with 20% FCS. Visually confluent monolayers
were formed after overnight incubation. To measure endothelial-dependent neutrophil
adherence, HUVE were pretreated with 5% FCS and medium alone (control) or medium
containing test reagents for 4 h and then washed with two well-volume exchanges of
medium supplemented with 5% FCS. Polymyxin B (10 kg/ml) was included in the wash
medium to inactivate free or surface-bound LPS. "Cr-labeled neutrophils were then
added (250 ;1/well), and the cells were incubated for 30 min at 37°C. After incubation,
HUVE were washed with a single well-volume exchange of medium to remove nonadher-
ent neutrophils. The cell layer and the remaining adherent "Cr-labeled neutrophils were
solubilized by addition of 1 N NH40H and the lysates were counted in a gamma counter
(Micromedic Systems, Inc., Horsham, PA).
B Cell Mitogenicity Assay.
￿
B cell mitogenicity of LPS and deacylated LPS was measured
as previously described (10). LPS or deacylated LPS was added to single-cell suspensions
of C3H/HeN mouse spleen in 96-well microtiter plates; cultures (0.2 ml) contained
300,000 cells in RPMI 1640 with antibiotics and 5% FCS. After 24 h, methyl-[5H]-
thymidine (0.5 uCi) was added, and the amount of radioactivity incorporated into the
cells in each well was measured 18 h later.
Results
Deacylated LPS Lacks Activity.
￿
Pretreatment of HUVE with LPS increased the
adherence of subsequently added neutrophils. Neutrophil adherence to HUVE
pretreated with LPS (13 ng/ml for 4 h) was 31 ± 2% compared with 4 ± I%
adherence to untreated HUVE (means ± SE of seven experiments). In contrast,
pretreatment of HUVE with enzymatically deacylated LPS did not promote the
adherence of subsequently added neutrophils. Neutrophil adherence to HUVE
pretreated with deacylated LPS (126 ng/ml for 4 h) was 6 ± 2% compared with
8 ± 2% adherence to untreated HUVE (means ± SE of four experiments).
Partial removal of the nonhydroxylated fatty acids by graded exposure of LPS
to the acyloxyacyl hydrolase produced LPS preparations with intermediate
activity. Neutrophil adherence to HUVE pretreated with deacylated LPS de-
creased with the extent of enzymatic deacylation (Fig. 1). In contrast to the lack
of activity of deacylated LPS in promoting neutrophil adherence of HUVE, the
B cell mitogenic activity of LPS was only minimally affected by enzymatic
deacylation of LPS (Fig. 2).
Deacylated LPS Inhibits the Activity ofLPS.
￿
Coincubation with deacylated LPS
reduced neutrophil adherence induced by pretreatment of HUVE with LPS.
Complete inhibition was observed when the ratio of deacylated LPS to LPS
(wt/wt) was >20-fold (Fig. 3). Deacylated S. typhimurium LPS also inhibited E.
coli LPS. Neutrophil adherence to HUVE pretreated for 4 h with E. coli LPS1396
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FIGURE 1 .
￿
Neutrophil adherence to HUVE pretreated with LPS
decreases as the extent of LPS deacylation increases. HUVE were
pretreated for 4 h with LPS preparations (6.7 ng/ml) that differed
in the extent ofremovalof theacyloxyacyl-linked nonhydroxylated
fattyacids. HUVE were then washed twiceand"Cr-labeled neutro-
phils were added. Percent neutrophil adherence was determined
after a 30-min incubation. Values represent the mean of four
replicate wells for each LPS preparation in one representative
experiment.
FIGURE 2.
￿
Deacylated LPS fails to induce neutrophil adher-
ence to HUVE, but retains activity as a B cell mitogen. (Top)
Murine spleen cell suspensions were treated for 18 h with
medium containing LPS (closed circles) or medium containing
deacylated LPS (open circles) in varying concentrations. ['Hl-
Thymidinewasaddedand thestimulation indexwasdetermined
after an 18-h incubation. Values represent the average of four
determinations. (Bottom) HUVE were pretreated for 4 h with
medium containing LPS (closed circles) or medium containing
deacylated LPS (open circles) in varying concentrations. HUVE
were then washed twiceand"Cr-labeled neutrophils were added
for a 30-min incubation. Values represent the means of four
replicate wells in one representative experiment.
(25 ng/ml) was 31 ± 2%, but was reduced to 3 ± 1 % when deacylated S.
typhimurium LPS (268 ng/ml) was added with the E. coli LPS (means ± SD of 4
replicate wells). Maximum inhibition was observed when deacylated LPS was
added to HUVE 30 to 60 min before LPS; but addition of deacylated LPS to
HUVE as late as 60 min after the addition of LPS significantly reduced subse-
quent neutrophil adherence (Fig. 4).
Similar to LPS, pretreatment of HUVE with rhTNF-a (1, 19) or rhIL-1 (1, 2,
20) produces an increase in neutrophil adherence to HUVE. Deacylated LPS
did not inhibit neutrophil adherence induced by pretreatment of HUVE with
either rhTNF-a or rhIL-1 (Table I). Like deacylated LPS, lipid X and mono-
phosphoryl lipid A (21) failed to induce the adherence-promoting activity in30
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FIGURE 3. Deacylated LPS inhibits neutrophil adherence to
HUVE induced by pretreatment of HUVE with LPS. HUVE
were pretreated for 30 min with deacylated LPS in varying
concentrations. Without washing, LPS (13.4 ng/ml) was then
added, and HUVE were incubatedforan additional 4h. HUVE
were then washed and "Cr-labeled neutrophils were added.
Percent neutrophil adherence was determined after a 30-min
incubation. Values represent the mean of two replicate wells at
each ratio (wt/wt) of deacylated LPS to LPS in one representa-
tive experiment.
FIGURE 4. Neutrophil adherence to LPS-pretreated
HUVE is inhibited when deacylated LPSis addedafter LPS.
HUVE were pretreated with LPS (13.6 ng/ml) for 4 h.
Deacylated LPS(268 ng/ml) was added to HUVE with LPS
(0),or at various timesbefore (-)or after(+) LPSwasadded.
At theend ofthe4-h incubation period, HUVE were washed
twiceand"Cr-labeled neutrophils were added. Percentneu-
trophiladherencewasdetermined aftera 30-min incubation.
Percent inhibition represents the reduction of neutrophil
adherence to HUVE pretreated with both deacylated LPS
and LPS compared with adherence to HUVE pretreated
only with LPS.
HUVE. Monophosphoryl lipid A, however, did notreduce neutrophil adherence
induced by pretreatment of HUVE with LPS, and lipid X reduced adherence
minimally (Table II).
As additional controls, the deacylation reaction mixture was incubated with
and without enzyme, treated with ethanol, and stored as described for LPS and
deacylated LPS. Pretreatment of HUVE for 4 h with the deacylation reaction
mixture or the reaction mixture plus enzyme did not increase subsequent
neutrophil adherence, and the reaction mixture or the reaction mixture plus
enzyme did not inhibit neutrophil adherence to HUVE induced by LPS (data
not shown).
Discussion
Much is known about the chemical structure of LPS, including the nature of
the long-chain fatty acids that are attached by ester and amide linkages to the
diglucosamine backbone of the lipid A moiety (22). Typical of LPS from
Enterobacteriaceae, Salmonella typhimurium LPS has 3-hydroxytetradecanoyl (3-
OH-14:0) residues esterified to the 3' and 3 positions, and amide linked to the
2' and 2 positions, ofthe diglucosamine backbone ofthe lipid A moiety (23). In
addition, the hydroxyl groups of the 3-OH-14:0 residues on the nonreducing
sugar of the diglucosamine backbone are substituted with nonhydroxylated acyl1398 DEACYLATED LIPOPOLYSACCHARIDE
TABLE I
Deacylated LPS Inhibits Neutrophil Adherence to HWE Pretreated
with LPS but notwith rhTNF-a or rhIL-I
Pretreatment of HUVE
￿
Neutrophil adherence
Medium
￿
4 t 1
Deacylated LPS
￿
2 ± 1
LPS
￿
34 t 1
LPS anddeacylated LPS
￿
14 ± 1
rhTNF-a
￿
46 ± 9
rhTNF-aand deacylated LPS
￿
50 t 8
rhIL-1
￿
43 t 4
rhIL-1 and deacylated LPS
￿
42 t 4
HUVE were pretreated for 30 min with deacylated LPS(150 ng/ml) or
medium. Without washing, medium alone(control) or medium contain-
ing LPS (15 ng/m)), rhTNF-a (20 ng/ml), or rhIL-1 (200 pg/ml) was
then added. Afteranadditional 4h incubation, HUVE were then washed
and"Cr-labeled neutrophils were added. Percent neutrophil adherence
wasdetermined aftera 30-min incubation. Values representmean ± SD
of four replicate wells.
p< 0.001 compared with LPS.
TABLE 11
Deacylated LPS but notMonophosphoryl Lipid A or Lipid XInhibits
Neutrophil Adherence to HWEPretreated with LPS
HUVE were pretreated with medium or medium containing deacylated
LPS (300 ng/ml), monophosphoryl lipid A (5.0 Wg/ml), or lipid X (2.5
Aag/ml) for 30 min. Withoutwashing, medium alone or medium contain-
ing LPS (15 ng/ml) was then added to HUVE and incubated for an
additional 4 h. HUVE were then washed and "Cr-labeled neutrophils
were added. Percent neutrophil adherence was determined after a 30-
min incubation. Values representmeans ± SD of four replicate wells.
* p< 0.001 compared to LPS.
<0.05 compared with LPS.
chains. Human neutrophils (10, 13) and macrophages from both normal and
endotoxin-hyporesponsive mice (24) have an enzyme (or enzymes) that deacylates
S. typhimurium LPS by preferential hydrolysis of the acyloxyacyl bonds linking
Pretreatment of HUVE Neutrophil Adherence
Medium 2±1
Deacylated LPS 2t1
Monophosphoryl lipid A 3 1
Lipid X 1t1
LPS 3014
LPS and deacylated LPS 3±1*
LPS and monophosphoryl lipid A 2812
LPS and lipid X 24 t 2tPOHLMAN ET AL.
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the nonhydroxylated fatty acids to the 3-OH-14 :0 residues. Compared with LPS,
deacylated LPS is 100-fold less active in the dermal Shwartzman reaction,
although it still retains significant activity as a B cell mitogen (reference 10 and
Figure 2). Similar behavior in these tests had been reported previously (25, 26)
for lipid A analogs that lack acyloxyacyl groups.
In vitro, LPS induces an endothelial cell surface activity that promotes neutro-
phil adherence (1, 2). In contrast, pretreatment of HUVE with enzymatically
deacylated LPS, lipid X, or monophosphoryl lipid A did not induce neutrophil
adherence to HUVE. The inability of these LPS-related compounds to promote
neutrophil adherence to endothelium correlates with their failure to provoke the
dermal Shwartzman reaction, in agreement with previous evidence (8) that this
reaction is, in part, a neutrophil-dependent phenomenon.
Of particular interest was our finding that deacylated LPS completely inhibits
LPS-induced neutrophil adherence to HUVE when the ratio of deacylated LPS
to LPS (wt/wt) was >20-fold. Deacylated S. typhimurium LPS inhibited E. coli
LPS as well as S. typhimurium LPS. The inhibitory effect of deacylated LPS was
specific for LPS, since deacylated LPS did not prevent increased neutrophil
adherence induced by pretreatment of HUVE with rhIL-1 or rhTNF-a.
Complete inhibition of neutrophil adherence to LPS-pretreated endothelium
was observed only with deacylated LPS, whereas lipid X and monophosphoryl
lipid A (even in large molar excess) did not inhibit adherence. The mechanism
by which deacylated LPS inhibits LPS-induced neutrophil adherence to HUVE
is unknown. Our data are consistent with the hypothesis that deacylated LPS
competitively inhibits the binding of LPS to one or more cell-surface or intra-
cellular targets. Although LPS binding to animal cells has been thought to occur
by a nonspecific hydrophobic interaction of the lipid A moiety with cell mem-
branes (27), recent experiments have suggested that macrophages have surface
molecules that recognize both the polysaccharide (28) and the lipid A (29)
components of LPS. It is thus attractive to speculate that the oligosaccharide
chain, which is attached to lipid A in deacylated LPS but not in lipid X or
monophosphoryl lipid A, may contribute to the inhibition observed. Studies to
characterize the binding of LPS and deacylated LPS to HUVE, as well as to each
other, are in progress. Whether deacylated LPS inhibits other inflammatory
responses induced by LPS, such as IL-1 or TNF-a production by mononuclear
phagocytes, is also currently under investigation.
Duncan and Morrison (30) proposed that processed LPS released from mac-
rophages serves as an immunostimulant to enhance the host response to bacterial
invasion. Consistent with this hypothesis is the observation (10) that deacylation
of LPS by the leukocyte acyloxyacyl hydrolase dramatically reduces its tissue
toxicity while preserving some of its immunostimulatory potential . Our data
suggest that deacylation of LPS may further modulate the host response to Gram-
negative bacteria by providing a competitive inhibitor of some LPS effects on
host target cells.1400
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Summary
Selective deacylation of the nonhydroxylated fatty acids from S. typhimurium
LPS by an acyloxyacyl hydrolase isolated from leukocytes reduces toxic activity
of LPS in vivo. We examined the effect of deacylated LPS on neutrophil
adherence to human umbilical vein endothelial cells (HUVE). Pretreatment of
HUVE with LPS (13 ng/ml for 4 h) produced a marked increase in the adherence
of subsequently added neutrophils. In contrast, there was no increase in the
adherence of neutrophils to HUVE pretreated with deacylated LPS (up to 260
ng/ml for 4 h). Neutrophil adherence to HUVE pretreated with LPS decreased
as the degree of LPS deacylation increased.
Deacylated LPS was not only itself inactive, but it inhibited neutrophil-endo-
thelial interactions induced by LPS. Neutrophil adherence to HUVE pretreated
with LPS was inhibited by deacylated LPS in a dose-dependent manner. Complete
inhibition of adherence was observed at a 20:1 ratio (wt/wt) of deacylated LPS
to LPS. Significantly, inhibition of neutrophil adherence to HUVE pretreated
with LPS was observed even when deacylated LPS was added to HUVE up to
60 min afterLPS. Deacylated LPS, however, did not inhibit neutrophil adherence
induced by pretreatment of HUVE with IL-1 or TNF-a.
We conclude that enzymatic deacylation of the nonhydroxylated fatty acids of
LPS abolishes the ability of LPS to induce surface expression of a neutrophil
adherence promoting activity in HUVE. Furthermore, deacylated LPS inhibits
neutrophil adherence to HUVE induced by LPS, perhaps by preventing the
interaction of LPS with a specific cell-surface or intracellular target.
We gratefully acknowledge Catherine L. Hall and Marva F. Griffith for preparing the
enzyme used to deacylate LPS for these experiments and Lou Limtiaco for expert word
processing.
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